Documento de consenso de asma grave en adultos. Actualización 2022

• DOI: 10.1016/j.opresp.2022.100192
• Publication Date: 2022-07-02T16:07:10Z
• Authors: Francisco Javier ...; Marina Blanco-Apa...; Francisco Casas-M...; Vicente Plaza; Francisco Javier ...; José Ángel Carret...; Manuel Castilla-M...; Carolina Cisneros; David Diaz-Pérez; Christian Domingo...; Eva Martínez-Moragon; Xavier Muñoz; Alicia Padilla-Galo; Miguel Perpiñá-To...; Gregorio Soto-Campos
• Keywords: 0301 basic medicine; Severe asthma; RC705-779; Asma grave; Diagnóstico; Follow-up; Seguimiento; 3. Good health; Treatment; Diseases of the respiratory system; Documento De Consenso; 03 medical and health sciences; Anticuerpos monoclonales; Diagnosis; follow-up; Tratamiento; Monoclonal antibodies

Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease in order to minimize their symptomatology. For this 2020 consensus update, a literature review was conducted by the authors. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.